Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



FDA Commish Joins Blogosphere

The blogging bandwagon just got a little bit bigger. Two weeks ago, FDA Commissioner Andrew von Eschenbach joined the millions of bloggers around the world.

Even though the FDA commish often complains that the agency is overworked and strapped for cash, he found the time to start what appears to be a relatively interesting peek inside the agency. Investors rarely get such a look at the FDA's psyche, thought process, and viewpoints on current events outside of advisory panel hearings, so "Andy's Take" -- also available as an MP3 podcast -- could provide some valuable insight about the FDA's leader.

In the blog's second post last week, von Eschenbach candidly discussed the FDA's role in the Baxter (NYSE: BAX  ) heparin recall, its efforts to prevent such drug contamination, and its plans to step up oversight of foreign drug manufacturers.

I'm generally pretty critical of some of the things going on at the FDA, like its continual missing of drug deadlines (CV Therapeutics (Nasdaq: CVTX  ) was only the most recent example), and its repeated requests for more funding this year after just getting a massive raise in PDUFA fees last year.

Since von Eschenbach took over as official FDA Commissioner in late 2006, and following last year's reauthorization of the Prescription Drug User Fee Act, the FDA's undergone many changes. Some have benefitted drugmakers and consumers; others were less helpful. Any extra openness from the agency, including "Andy's Take," will undoubtedly give investors a slightly better idea of how the agency works, and what chances drug candidates have of winning its approval. Sounds good to me.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 610485, ~/Articles/ArticleHandler.aspx, 10/24/2016 11:33:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 hours ago Sponsored by:
DOW 18,223.03 77.32 0.43%
S&P 500 2,151.33 10.17 0.47%
NASD 5,309.83 52.43 1.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 4:00 PM
BAX $48.44 Up +0.26 +0.54%
Baxter CAPS Rating: ****
CVTX.DL $20.01 Down +0.00 +0.00%
CV Therapeutics CAPS Rating: **